Introduction {#S0001}
============

Despite significant advances in diagnostic evaluations and therapeutic interventions, congestive heart failure (CHF) remains a major and growing clinical reality characterized by high morbidity, mortality and economic burden \[[@CIT0001]\]. Congestive heart failure affects 2% of the United States population, with an estimated 5.1 million Americans aged 20 years and older affected, and by 2030 the prevalence of CHF will increase by 25% \[[@CIT0002]\]. The incidence of CHF is approximately 10 per 1000 among people over 65 years of age, with African Americans having the highest risk of developing CHF, followed by Latinos, whites, and Asian Americans (4.6, 3.5, 2.4 and 1.0 per 1000 person years, respectively) \[[@CIT0003]\]. Early hospital readmission for CHF is a major health care and economic problem in the United States, especially in African Americans and Latinos.

Congestive heart failure is a progressive medical problem with concomitant high mortality. One in 9 deaths in the United States involve heart failure \[[@CIT0002]\]. Congestive heart failure accounts for approximately 277,000 deaths annually in the United States and approximately 34% of cardiovascular-related deaths. Approximately 50% of persons diagnosed with CHF will die within 5 years \[[@CIT0002]\]. Mortality is closely associated with decompensated CHF requiring hospital admission, particularly frequent admissions and early (60 days or less) readmissions \[[@CIT0004]\]. Despite advances in the management of CHF and multiple studies investigating the predictors of early CHF readmission, the rates remain unacceptably high. Congestive heart failure remains the leading cause of hospital admission for patients over 65 years of age, and readmissions have implications for patients, hospitals and third-party payers. Congestive heart failure readmission portends a poor prognosis for the patient, with a median survival of 18 to 24 months after hospital discharge \[[@CIT0005]\]. Three percent of African Americans are affected by CHF compared to 2% of the general population \[[@CIT0006]\]. Notably, African Americans have a disproportionately high incidence of hypertension (32%) as an etiology of left ventricular dysfunction when compared to white patients (4%) \[[@CIT0007], [@CIT0008]\].

A retrospective analysis of the military health system\'s TRICARE program revealed that a significant proportion of African Americans and Latinos received less evidence-based CHF-related care in terms of β-blocker and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) therapy compared to whites (53.4% and 49.2% vs. 58.3%; *p* \< 0.0001) \[[@CIT0009]\]. Interestingly, this study found no significant differences in the odds of rehospitalization in the same groups. An analysis of Medicare patients from 2006 to 2008 showed that Latino patients had a higher rate of CHF readmission compared to whites (27.9% vs. 25.9%, *p* \< 0.001) \[[@CIT0010]\]. This study found a similar trend in African Americans, where the CHF readmission rate was higher compared to whites (27.9% vs. 27.1%, *p* \< 0.01) \[[@CIT0011]\]. Congestive heart failure also results in a significant financial burden, with 2030 total cost projections estimated to increase by almost 120% to \$70 billion from current expenditures of \$32 billion annually \[[@CIT0002]\]. Hospitalizations account for an estimated 75% of the direct costs associated with heart failure.

Early CHF readmissions are often related to clinical and patient concerns (comorbidity management, medical non-compliance, lack of early outpatient follow-up care, lack of support structures at home) which are not resolved during the index hospitalization. Disease progression with worsening severity also contributes to early readmissions \[[@CIT0012]\]. Therefore, early readmissions are increasingly being viewed as avoidable and an indicator of poor care or an inadequately coordinated health system \[[@CIT0013]\]. For these reasons, in addition to the significant associated costs, the Centers for Medicare and Medicaid Services (CMS) began public reporting of hospital early readmission rates for CHF and also implemented penalties for hospitals with high and excessive early readmission rates \[[@CIT0014]\]. Resource-limited hospitals serving low-income populations and communities, which often have high early readmission rates for CHF, will be most affected by these measures. The reduction in reimbursement to hospitals and healthcare systems already struggling with the challenges of providing quality care to underserved and vulnerable patient populations will likely exacerbate the very concerns CMS hopes to address. Therefore, these hospital and healthcare systems must implement protocols to identify CHF patients at high risk for readmission and allocate resources to reduce their CHF early readmission rates.

There is a paucity of studies evaluating the relative importance of the previously identified predictors of early readmission specifically for a predominantly African-American and Latino, underserved, urban, and low-income population \[[@CIT0015]\]. Additionally, there are likely precipitants of decompensated CHF that are unique and represent more of a burden in this patient population because of socioeconomic factors \[[@CIT0003]\]. The few prior studies that were conducted in these populations involved only small numbers of patients followed over a short study period. Therefore, the aim of this study is to identify the clinical factors and predictors of early (\< 60 day) readmission for CHF specifically for a predominantly African-American and Latino underserved urban population. Determination of the relative contribution of these factors and predictors will enable identification of high-risk patients who would benefit from a more intensified, goal-directed, customized, multidisciplinary management program initiated during their index admission and continued after discharge. These interventions will ideally be effective in reducing CHF readmissions, improving patients' morbidity and mortality, and reducing health care costs while preserving hospital reimbursements.

Material and methods {#S0002}
====================

A retrospective study was conducted at Harlem Hospital Center in New York City after obtaining Institutional Review Board approval for the research protocol. Data were collected for 685 consecutive adult patients (≥ 18 years old) admitted for decompensated CHF (systolic and diastolic heart failure) from January, 2009 to December, 2012 to determine the clinical factors associated with early CHF readmission. Systolic CHF was defined as an echocardiographic left ventricular ejection fraction of \< 40% in a patient presenting with signs and symptoms of CHF \[[@CIT0015]\]. Diastolic heart failure was defined as a preserved, normal left ventricular ejection fraction with diastolic dysfunction by echocardiography in a patient presenting with signs and symptoms of CHF. Patients with diastolic CHF were identified based on previously established guidelines \[[@CIT0016]--[@CIT0018]\]. Variables, including patient demographics, comorbidities (including substance abuse supported by patient history and blood and urine toxicology studies, primarily alcohol and cocaine), laboratory studies, and medical therapy prescribed at the time of discharge were compared between CHF patient admissions resulting in an early readmission for CHF, defined as within 60 days, and those not resulting in early readmission.

Patients were all adults (≥ 18 years old) admitted and discharged with a primary diagnosis of decompensated CHF from the internal medical inpatient service. Patients were excluded if they were known to have stable CHF but admitted for an unrelated medical problem with no clinical evidence of CHF decompensation. The diagnosis of CHF was made clinically based on symptoms and signs of pulmonary and systemic venous congestion and/or manifestations of tissue hypoperfusion \[[@CIT0019]\]. Echocardiographic findings, including left ventricular ejection fraction and evidence of diastolic dysfunction, and biomarkers such as brain natriuretic peptide (BNP) were also incorporated into the diagnostic evaluation. The majority of the patients were admitted through the Emergency Department, but some were transferred from other services (primarily medicine or subspecialty clinics).

Statistical analysis {#S20003}
--------------------

The baseline characteristics were compared between early admission and no early admission groups using the two-sample *t*-test or the Wilcoxon rank-sum test for continuous variables and χ^2^ tests for categorical variables. χ^2^ tests were used to investigate the association between early readmission and clinical factors. Univariate logistic regression was used to estimate the probability of early readmission (PER) associated with each of these clinical factors. Baseline characteristics and clinical factors with *p*-values \< 0.20 were entered as candidate variables for stepwise multiple logistic regression. Stepwise logistic regression analysis was conducted to identify significant independent factors associated with early admission. The odds ratios obtained from stepwise logistic regression were used to assign the scores to the independent clinical factors associated with early readmission points. A weighted scoring system was created by rounding all regression coefficients in the final model to the nearest integer.

Results {#S0004}
=======

Six hundred eighty-five consecutive hospital patient admissions for decompensated CHF were evaluated in the study. One hundred thirty-six early readmissions for decompensated CHF were identified, resulting in an early readmission rate of 19.85%. The baseline characteristics for patients who experienced an early CHF readmission, for those who did not experience an early CHF readmission, and p values for comparison are presented in [Table I](#T0001){ref-type="table"}. There were no significant differences in medical therapy prescribed at hospital discharge. The use of combined isosorbide dinitrate plus hydralazine (BiDil) therapy among a predominantly African-American patient population in this study was based on the A-Heft trial \[[@CIT0020]\].

###### 

Baseline characteristics of heart failure study patients

  Characteristics                                 Early re-admission   No early re-admission   *P*-value
  ----------------------------------------------- -------------------- ----------------------- -----------
  Patients                                        136                  549                     
  Age \[years\]                                   63.7 ±15.2           63.6 ±15.1              0.973
  Length of stay \[days\]                         5.9 ±5.6             8.0 ±15.6               0.009
  Admission BNP \[pg/ml\]                         1636.1 ±1220.8       1298.6 ±1272.0          \< 0.0001
  Gender:                                                                                      0.7773
   Female                                         66 (48.5%)           259 (47.2%)             
   Male                                           70 (51.5%)           290 (52.8%)             
  Ethnicity:                                                                                   0.0087
   African-American                               125 (91.9%)          437 (79.6%)             
   Latino                                         9 (6.6%)             78 (14.2%)              
   Other                                          2 (1.5%)             34 (6.1%)               
  Body mass index \> 30 kg/m^2^                   41 (30.1%)           236 (43.5%)             0.0045
  Hypertension                                    126 (92.6%)          498 (90.7%)             0.4778
  Diabetes mellitus                               43 (31.6%)           231 (42.1%)             0.0258
  Dyslipidemia                                    37 (27.2%)           134 (24.4%)             0.4997
  Chronic obstructive pulmonary disease           43 (31.6%)           55 (10.0%)              \< 0.0001
  Coronary artery disease                         36 (26.5%)           137 (25.0%)             0.7156
  Atrial fibrillation                             41 (30.1%)           96 (17.5%)              0.001
  Human immunodeficiency virus disease            18 (13.2%)           25 (4.6%)               0.0002
  Renal disease GFR \< 60 ml/min                  53 (39.0%)           215 (39.2%)             0.9673
  Renal disease GFR 30--59 ml/min                 33 (24.3%)           176 (32.1%)             0.0772
  Renal disease GFR \< 30 ml/min                  54 (39.7%)           158 (28.8%)             0.0136
  Active smoker                                   75 (55.1%)           233 (43.7%)             0.017
  History of substance abuse                      57 (41.9%)           144 (27.0%)             0.0007
  Aspirin                                         108 (79.4%)          416 (75.8%)             0.3704
  Statin                                          96 (70.6%)           338 (61.7%)             0.0535
  β-Blocker                                       78 (57.4%)           317 (58.0%)             0.8992
  ACEI/ARB                                        91 (66.9%)           324 (59.0%)             0.0916
  Digoxin                                         24 (18%)             73 (13%)                0.198
  Diuretics                                       114 (84%)            451 (82%)               0.646
  BiDil (isosorbide dinitrate plus hydralazine)   39 (28.7%)           116 (21.2%)             0.061
  Spironolactone                                  6 (4.4%)             29 (5.3%)               0.671

BNP -- brain natriuretic peptide, GFR -- glomerular filtration rate, ACEI -- angiotensin-converting enzyme inhibitor, ARB -- angiotensin receptor blocker.

[Table II](#T0002){ref-type="table"} shows the clinical parameters associated with early readmission with calculated odds ratios, 95% confidence intervals, and *p*-values. [Table III](#T0003){ref-type="table"} shows the significant independent baseline characteristics and clinical factors associated with early readmission using stepwise logistic regression analysis with a proposed scoring system for early CHF readmission. The odds ratio integer was used to assign each clinical factor a point.

###### 

Clinical parameters associated with early readmission

  Clinical factor                       Early readmission   No early readmission   Odds ratio, (95% CI)   *P*-value   Probability of early readmission (PER) (%)
  ------------------------------------- ------------------- ---------------------- ---------------------- ----------- --------------------------------------------
  Smoker                                75/136 (55%)        233/533 (44%)          1.6 (1.1--2.3)         0.0170      24.4
  African-American                      125/136 (92%)       437/549 (80%)          2.9 (1.5--5.6)         0.0008      22.2
  Systolic heart failure                92/132 (70%)        289/510 (57%)          1.8 (1.2--2.7)         0.0066      24.1
  COPD                                  43/136 (32%)        55/549 (10%)           4.2 (2.6--6.6)         \< 0.0001   43.9
  Atrial fibrillation                   41/136 (30%)        96/549 (17%)           2.0 (1.3--3.1)         0.0010      29.9
  HIV disease                           18/136 (13%)        25/549 (5%)            3.2 (1.7--6.1)         0.0002      41.9
  Renal disease GFR \< 30 ml/min        54/136 (40%)        158/549 (29%)          1.6 (1.1--2.4)         0.0136      25.5
  History of substance abuse            57/136 (42%)        144/534 (27%)          2.0 (1.3--2.9)         0.0007      28.4
  BNP (≥ 1200 pg/ml)                    73/136 (54%)        213/544 (39%)          1.8 (1.2--2.6)         0.0022      25.5
  Length of hospital stay (≥ 25 days)   2/136 (1%)          34/544 (6%)            0.2 (0.1--0.9)         0.0297      5.6

COPD -- chronic obstructive pulmonary disease, HIV -- human immunodeficiency virus, GFR -- glomerular filtration rate, BNP -- brain natriuretic peptide.

###### 

Proposed scoring system for early readmission

  Clinical factor                          Odds ratio   Assigned points
  ---------------------------------------- ------------ -----------------
  African-American                         2.2          2
  Chronic obstructive pulmonary disease    6.4          6
  Atrial fibrillation                      2.3          2
  Human immunodeficiency virus disease     3.4          3
  Renal disease with GFR \< 30 ml/min      2.7          3
  History of substance abuse               1.7          2
  Systolic heart failure                   1.9          2
  No ACEI or ARB therapy after discharge   1.8          2

GFR -- glomerular filtration rate, ACEI -- angiotensin-converting enzyme inhibitor, ARB -- angiotensin receptor blocker.

The assigned points of the independently significant clinical factors for early CHF readmission were formulated into a risk score to assess the relative probability of early readmission based on a cumulative scoring system, which is summarized in [Table IV](#T0004){ref-type="table"}. While this scoring system needs further validation in prospective studies, it establishes the possibility of developing a risk stratification model among the studied patient population regarding early CHF readmission.

###### 

Total risk score and its correlation with risk of early readmission

  Risk Score   Frequency     Risk of early readmission (%)
  ------------ ------------- -------------------------------
  \< 5         161 (23.5%)   2.50
  5--9         325 (47.5%)   17.80
  10--14       135 (19.7%)   49.60
  15--20       13 (1.9%)     53.80

Discussion {#S0005}
==========

The clinical factors in this study independently associated with early CHF readmission after an index hospitalization for CHF among a predominantly African-American and Latino underserved urban population have a specific impact on the pathophysiology and therapeutic management of heart failure. They reflect a unique cohort of clinical predictors for early CHF readmission that affect a specific patient population which is at particularly high risk for adverse outcomes related to CHF. In addition, African Americans and Latinos are at disproportionately high risk regarding the comorbidities identified in this study as predictors for early CHF readmission.

Chronic obstructive pulmonary disease (COPD) exacerbates the progression of CHF through mechanisms related to accelerated pulmonary hypertension and right-sided heart failure, which further compromises cardiac output \[[@CIT0021]\]. In addition, patients with COPD have limited pulmonary reserve and likely experience CHF decompensation with less pulmonary congestion \[[@CIT0022]\]. The interdependent physiology of the cardiopulmonary system and a rapid cycle of progressive deterioration related to shared structural pathology likely explain why COPD has the strongest association with early CHF readmissions \[[@CIT0023], [@CIT0024]\]. Human immunodeficiency viral (HIV) disease is a cause of CHF, and these patients are managed for two complicated chronic illnesses, with significant drug interactions regarding their respective medical therapies \[[@CIT0025]\]. The poly-pharmacy, including anti-retroviral and CHF medications, likely results in drug adverse effects which reduce compliance and precipitate CHF exacerbations \[[@CIT0026]\].

The increased morbidity and mortality associated with concomitant renal disease with a glomerular filtration rate (GFR) less than 30 ml/min/1.73 m^2^ and CHF are well documented, including perennial activation of the renin-angiotensin-aldosterone system, accelerated volume retention, and decreased diuresis \[[@CIT0027]\]. Echocardiographic indices may be used to assess left ventricular diastolic dysfunction in patients with chronic kidney disease \[[@CIT0028]\]. Syndecan-4 may be a useful biomarker for predicting adverse left ventricular remodeling in patients with CHF due to dilated cardiomyopathy \[[@CIT0029]\]. Atrial fibrillation invariably results in episodic rapid ventricular rates, which further compromise diastolic filling and cardiac output in the setting of CHF, with resultant decompensation requiring intervention \[[@CIT0030], [@CIT0031]\]. Higher levels of physical activity in older community-dwelling adults were associated with a lower incidence of incident CHF \[[@CIT0032]\]. Management of CHF in older adults is extensively discussed elsewhere \[[@CIT0033]--[@CIT0036]\].

The association between African-American ethnicity and early CHF readmissions is more complicated and likely involves the interaction of genetic, clinical and social factors. Studies have suggested that African Americans experience more rapid progression of CHF due to genetic polymorphisms \[[@CIT0037]\]. In addition, the social realities of disproportionate poverty and limited access to medical care and therapeutic interventions, which contribute to continuing healthcare disparities, must also be considered. The increased morbidity and mortality associated with systolic heart failure compared to diastolic heart failure are related to the frequent irreversibility of decreased left ventricular function in these patients \[[@CIT0038]\]. The more progressive clinical cycle of structural heart disease and pathological neurohormonal compensatory mechanisms likely accelerate the rate of early decompensation \[[@CIT0039]--[@CIT0041]\].

The evidence supporting the use of ACEI or ARB therapy in patients with systolic CHF has been well established. Patients unable to take these medications would be expected to experience increased morbidity and mortality from this disease \[[@CIT0042]\]. The clinical impact of a history of substance abuse (supported by patient history and blood and urine toxicology studies, primarily alcohol and cocaine) on the pathophysiology and therapeutic management of heart failure is multiple-faceted \[[@CIT0043]\]. These behaviors contribute to medical and healthcare non-compliance, rapid volume expansion, poor nutrition, myocardial ischemia, and worsening structural heart disease, and are invariably associated with limited social support systems, particularly in low-income communities \[[@CIT0044]--[@CIT0049]\].

The precise mechanisms by which the above individual clinical factors result in an independently significant increased risk of early CHF readmission, and whether they apply to other patient populations, will require additional and prospective studies for further delineation. Elucidating the clinical predictors of early CHF readmission in diverse patient populations remains an important focus of continuing investigation.

There have been many studies conducted on the predictors of early readmission for patients with CHF. However, only a few have investigated a predominantly African-American and Latino underserved urban population. Ghali *et al*. \[[@CIT0015]\] conducted a prospective study in a similar patient population. However, the study size was small (101 patients). The results of this research identified cardiac arrhythmias as a clinical factor and predictor of early CHF readmission, similar to our finding of an increased risk of early readmission among CHF patients with atrial fibrillation. The other predictors of early readmission identified by Ghali *et al*. included poor compliance with medications and diet, emotional and environmental issues, lack of guideline-based drug therapy, pulmonary infections and thyrotoxicosis \[[@CIT0015]\]. Philbin and DiSalvo \[[@CIT0050]\] investigated predictors of early readmission for CHF and the development of a risk score. However, because this study relied primarily on administrative data, psychosocial and behavioral variables were not investigated. In addition, although this research included a large study population (42,731) involving over 236 different hospitals in New York State, African Americans only represented 18.2% of the study population, as compared to 82% in the current investigation.

Vinson *et al*. \[[@CIT0051]\] conducted a study to investigate early readmission among 161 elderly patients with CHF and evaluated all-cause early readmissions. Decompensated CHF accounted for 57% of the early readmissions. The clinical factors and predictors associated with early readmission included prior history of CHF, four or more admissions within the preceding 8 years, CHF precipitated by acute myocardial infarction, and uncontrolled hypertension \[[@CIT0051]\]. Calvillo-King *et al*. \[[@CIT0052]\] conducted a systematic review to assess the impact of social factors on risk of readmission or mortality after hospitalization for community-acquired pneumonia and CHF. The study revealed that low socioeconomic status, lack of social support, being unmarried, and risk behaviors such as smoking and cocaine were significantly associated with readmission for CHF \[[@CIT0052]\].

These studies and the current investigation highlight the complicated, complex and diverse clinical and social factors that impact on the early readmission rates of CHF patients. Many multivariate risk scores have been developed to model patient outcomes in CHF patients \[[@CIT0053]\]. The system of scoring proposed in this study is both simple and convenient. The patient population analyzed in this study consists predominantly of African Americans (82% of patients) and Latinos (12.7% of patients) treated at a single medical center. Other ethnicities comprised only 5.3% of the study population. This represents a limitation of the study. Furthermore, it has been difficult to precisely describe the genetic profile of African Americans and Latinos, as they constitute a diaspora of immigrants from Africa and Latin America with contributions to the gene pool from other ethnic communities \[[@CIT0008]\]. Another major limitation of this study is the lack of validation of the early risk stratification scoring system in prospective studies. Implementing strategies to reduce early CHF readmission, with a primary goal of improving morbidity and mortality, will require both inter-disciplinary innovation and community-specific research and interventions. Another major limitation of this study was that data on anemia, post-discharge brain natriuretic peptide (BNP), and social economic factors were not collected in all patients.

Allocating resources for interventions in patients at particularly high risk for early CHF readmission will be more effective in reducing CHF readmissions, improving patients' morbidity and mortality, and reducing health care costs while preserving hospital reimbursements. Further validation of our risk scoring system prospectively is the subject of ongoing research with a goal of developing early CHF readmission prevention strategies which improve the morbidity and mortality of this high-risk patient population. The longer length of hospital stay in patients with no early readmission also needs further investigation.

In conclusion, developing a community-specific risk stratification model and scoring system to identify CHF patients at increased risk for early CHF readmission is an important strategy which may allow hospitals to reduce their early readmission rates. Once identified, these patients can be targeted for more intensified, goal-directed, customized, multidisciplinary management programs initiated during their index admission and continued after discharge. Allocating resources for interventions which involve those patients at particularly high risk for early CHF readmission will be more effective in reducing CHF readmissions, improving patients' morbidity and mortality, and reducing healthcare costs while preserving hospital reimbursements.

The current study proposes a risk scoring system for identification of CHF patients from a predominantly African-American and Latino underserved urban population based on independently significant clinical factors associated with early CHF readmission. Further validation of our risk scoring system prospectively is the subject of ongoing research with a goal of developing early CHF readmission prevention strategies which improve the morbidity and mortality of this high-risk patient population.
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